Featured Research

from universities, journals, and other organizations

Understanding night blindness and calcium

Date:
April 9, 2010
Source:
Johns Hopkins Medical Institutions
Summary:
Congenital stationary night blindness, an inherited condition that affects one's ability to see in the dark, is caused by a mutation in a calcium channel protein that shuttles calcium into and out of cells. Now, researchers have teased apart the molecular mechanism behind this mutation, uncovering a more general principle of how cells control calcium levels.

Congenital stationary night blindness, an inherited condition that affects one's ability to see in the dark, is caused by a mutation in a calcium channel protein that shuttles calcium into and out of cells. Now, researchers at the Johns Hopkins University School of Medicine have teased apart the molecular mechanism behind this mutation, uncovering a more general principle of how cells control calcium levels.

The discovery, published in the Feb. 18 issue of Nature, could have implications for several other conditions, including neurodegenerative diseases such as schizophrenia and Alzheimer's, Parkinson's and Huntington's diseases.

"Calcium is so crucial for normal functions like heart contraction, insulin control and brain function," says David Yue, M.D., Ph.D., a professor of biomedical engineering and director of the Calcium Signals Lab at Hopkins. "If calcium levels are off at any time, disease can ensue. Our new approach, watching calcium channels in action in living cells, allowed us to tease apart how they behave and how they're controlled and find a new module that could be targeted for drug design."

The aberrant calcium channel protein that causes this type of night blindness is missing the tail end of the protein. Yue's team compared the ability of this protein to full length versions by examining how well they can maintain electrical current in cells. Normal channels show a decrease in current with an increase in calcium levels. "We and others initially believed that the missing piece of the protein might behave to simply switch off the ability of elevated intracellular calcium to inhibit this current," says Yue. "Without this module, there's no way to down-regulate the calcium entering through these channels."

Yue's team found out, however, that in reality, this module functions in a far richer and nuanced manner. Calcium channels are known to be controlled by the protein CaM, which senses and binds to calcium, whereupon CaM binds to channels in a manner that inhibits their calcium transport function. To figure out how the tail module works in conjunction with CaM to control the calcium channel, the team used a molecular optical sensor tool that enabled them to see in live cells different levels of CaM, a controller of the channel protein. When CaM is abundant, the sensor glows cyan; when CaM is low, the sensor glows yellow.

The researchers found that the tail module doesn't simply turn off channel sensitivity to calcium; rather, the module smoothly retunes how sensitive channels are to CaM, and in turn how sensitive the transport function of channels is to intracellular calcium. In all, the tail module smoothly adjusts how much calcium enters cells. This manner of adjustment "may bear on many neurodegenerative diseases where calcium is dysregulated," says Yue.

With the optical sensor, Yue and his team next will examine other types of live cells, including nerve and heart cells, to measure whether changes in calcium channel behavior can lead to disease-like states.

This study was funded by the National Institute of Mental Health, the National Heart, Lung and Blood Institute and the National Institute on Deafness and Other Communication Disorders.

Authors on the paper are Xiaodong Liu, Philemon Yang, Wanjun Yang and David Yue, all of Johns Hopkins.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Journal Reference:

  1. Xiaodong Liu, Philemon S. Yang, Wanjun Yang, David T. Yue. Enzyme-inhibitor-like tuning of Ca2 channel connectivity with calmodulin. Nature, 2010; 463 (7283): 968 DOI: 10.1038/nature08766

Cite This Page:

Johns Hopkins Medical Institutions. "Understanding night blindness and calcium." ScienceDaily. ScienceDaily, 9 April 2010. <www.sciencedaily.com/releases/2010/04/100401101007.htm>.
Johns Hopkins Medical Institutions. (2010, April 9). Understanding night blindness and calcium. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100401101007.htm
Johns Hopkins Medical Institutions. "Understanding night blindness and calcium." ScienceDaily. www.sciencedaily.com/releases/2010/04/100401101007.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins